. Dépenses, De plus, ce chiffre est plus qu'hypothétique puisqu'il est peu probable que la cible soit totalement couverte

M. A. Abdul-ghani, L. Norton, and R. Defronzo, A Role of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in the Treatment of Type 2 Diabetes, vol.32, 2011.

. Afd-le-diabète-gestationnel-ou-diabète-de-grossesse, , 2016.

, Agence de la santé publique du Canada Réduire le risque d'apparition du diabète de type 2 et de ses complications, 2016.

, Assurance maladie Améliorer la qualité du système de santé et maîtriser les dépenses // Proposition pour l'année 2017, 2017.

J. Bailey, J. L. Gross, and A. Pieters, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomised, double-blind, vol.325

B. Bauduceau and . Bordier-sirvin, L Mesurons-nous suffisamment le coût des hypoglycémies?

/. Pratique, , pp.3-2017, 2017.

J. F. Blicklé, . Traitements, and . Du-diabète, , vol.20, 1999.

, Bohringer Ingelheim Résumé des caractéristique produit : Jardiance

. Bonnefont-rousselot, Diabète et stress oxydant, 2016.

. Coupez-l-activité-physique and . Diabète, , vol.11, 2016.

R. A. Defronzo, M. Hompesch, and S. Kasichayanula, Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes

E. Ferrannini, S. J. Ramos, and A. Salsali, Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise [Article] // Diabetes Care.-2010, vol.10

P. Gaede, H. Lund-andersen, and H. H. Parving, Effect of a multifactorial Intervention on Mortality in Type 2 Diabetes

. Green, M. A. Bethel, and P. Sk, Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease, Am Heart J, vol.166

H. Hadj, , 1910.

H. U. Häring, L. Merker, and E. Seewaldt-becker, Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, / Diabetes Care.-2014.-Emerging technology and therapeutics, vol.37

H. U. Häring, L. Merker, and E. Seewaldt-becker, Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes, vol.36, 2016.

, IGAS Evaluation de la prise en charge du diabète // Evaluation de la prise en charge du diabète, 2012.

. Inc and . Janssen, Monographie de produit Invokana®, 2017.

S. A. Jabbour, E. Hardy, and J. Sugg, Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind

M. Jazi, acidocétose euglycémique dans le diabète de type 2 traité avec un inhibiteur du cotransporteur sodium-glucose de type 2 [Article] // Can Fam Physicians, 2016.

T. Kadowaki, M. Haneda, and N. Inagaki, Empagliflozin monotherapy in japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled

, // advances in therapy.-2014.-Adis.-6, vol.31

S. Kasichayanula, M. Chang, and M. Hasegawa, Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus, vol.13

B. Komoroski, N. Vachharajani, and Y. Feng, Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus, Clinical Pharmacology & Therapeutics, vol.85

M. Krempf, Etude de la Saxagliptine sur la survenue d'événements cardiovasculaire chez des patients diabétiques de type 2 (étude SAVOR-TIMI 53): description de l'étude et des patients [Article] // Médecine des maladies métaboliques, vol.7, 2013.

F. J. Lavalle-gonzalez, A. Januszewicz, and J. Davidson, Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial, vol.56

S. Lecerf and . Médicaments, vers une remise à plat des critères d'évaluation, 2017.

M. Vernay, B. Salanave, and C. De-peretti, Metabolic syndrome and socioeconomic status in France : The French Nutrition and Health Survey, International Journal of Public Health, vol.58, 2006.

W. Meng, B. A. Ellsworth, and A. A. Nirschl, Discovery of Dapaglifozin: A potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

/. , J. Med. Chem, vol.51, pp.1145-1149, 2008.

M. Forxiga®, 13 Décembre, 2016.

A. Mourier, J. F. Gautier, and E. De-kerviler, Mobilization of visceral adipose tissue related to the improvement in insulin sensitivity in response to physical training in NIDDM. Effects of branchedchain amino acid supplements [Article] // Diabetes Care, vol.20

M. A. Nauck, D. Prato, S. Meier, and J. J. , Dapagliflozide versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin, vol.34, 2011.

I. J. Neeland, N. De-albuquerque-rocha, and . Mcguire, DK Cardiovascular effects of sodium glucose Cotransporteur 2 inhibitors: the search for the how and why, 01 Juillet, 2016.

, OCDE Panorama de la santé 2015 // Panorama de la santé, 2015.

O. Oms-/-diabète, , 2016.

, Oppert JM Activité physique et rpévention cardio-vasculaire, pp.2004-2051

A. Ptaszynska, K. M. Johnsson, and S. J. Parikh, Safety profile of dapagliflozin for type 2 diabetes: Pooled analysis of clinical studies for overall safety and rare events [Article] // Drug saf, Springer international publishing switzerland, vol.37

D. Raccah, Épidémiologie et physiopathologie des complications dégénératives du diabète sucré, vol.1, pp.29-42

H. Rahmoune, P. W. Thompson, J. M. Ward, C. D. Smith, G. Hong et al., J Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes, vol.12, 2005.

C. Rhéaume, P. Brassard, and . Le, , p.7, 2016.

P. Ricci, M. Chantry, and B. Detournay, Analyse économique des soins des personnes traitées pour diabète (étude entred, vol.41, 2001.

M. Roden, J. Weng, and J. Eilbracht, Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, Lancet Diabetes Endocrinol, vol.1, 2013.

J. Rosenstock, A. Jelaska, and G. Frappin, Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of iinsulin in obese inadequately controlled type 2 diabetes, 2014.

R. Pressl-wenger, A. Jornayvaz, and F. R. , Sécurité cardiovasculaire des antidiabétique [Article] // Revue médicale suisse, vol.12, 2016.

A. J. Scheen, G. Charpentier, and C. J. Ostqren, Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus, Diabetes Metal Res Rev, vol.26

G. Schernthaner, J. L. Gross, and J. Rosenstock, Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulphonylurea

, American Diabetes association, vol.36, 2013.

C. Sonesson, P. A. Johansson, and E. Johnsson, Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis [Article] // Cardiovascular diabetology, BioMed central, 2016.

K. Stenlöf, W. T. Cefalu, and K. A. Kim, Efficacy and safety of canagliflozin montherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise, vol.15, 2013.

I. M. Stratton, A. I. Adler, and H. A. Neil, Association of glycaemia with macrovascular and microvascular complication of type 2 diabetes (UKPDS 35): prospective observational study

/. Bmj, , vol.321

K. Strojek, K. H. Yoon, and V. Hruba, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate gycaemic control with glimerpiride: a randomized, 24-week, double-blind, p.13, 2011.

. Système-nerveux and . Diabète, , vol.10, 2016.

, The ADVANCE Collaborative Group Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes, N Engl J Med, vol.358, 2008.

. Tropeano, AE Mécanisme des complications du diabète : perspectives "thérapeutiques, vol.64

. Valensi-p,

P. Valensi, G. De-pouvourville, and N. Bernard, Treatment maintenance duration of dual therapy with metformin and sitagliptine ine type 2 diabetes: The ODYSSEE observational study, der Heuvel LP et Assink K et Willemsen M et al. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter, vol.41, pp.544-547

. Vergès-b-hyperlipidémie, , vol.1

B. Viollet, B. Guigas, S. Garcia, and N. , Cellular and molecular mechanisms of metformin: an overview [Article] // clinical science, vol.122

J. Wilding and P. Hollander, Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metforim and sulphonylurea: a randomised trial [Article] // The international journal of clinical practice, vol.12, 2013.

J. P. Wilding, V. Woo, and K. Rohwedder, Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years, vol.16, 2014.

, Yanick Farmer Denise Avard La composante génétique du diabète de type 2: suivi des progrès scientifiques du projet DGDG, vol.1, 2008.

.. J. Young-pr and . Endocrinologie, , 2011.

F. Zaccardi, D. R. Webb, and Z. Z. Htike, Efficacy and safety outcomes of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis

Z. Paul and G. Shaw, Nouvelle définition golbale du syndrome métabolique : raisonnement et résultats, vol.50, 2005.

B. Zinman, C. Wanner, and J. M. Lachin, Empagliflozin, cardiovadcular outcomes, and mortality in type 2 diabetes, vol.373, 2015.